Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 12, 1999, Pages 2841-2847

  Louie, Arnold ^a,b   Banerjee, Partha ^a,b   Drusano, George L ^a   Shayegani, Mehdi ^b   Miller, Michael H ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b WADSWORTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; CANDIDIASIS; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; FEMALE; FUNGUS CULTURE; KIDNEY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 0032785990     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.12.2841     Document Type: Article

References (24)

1. Adedoyin, A., J. F. Bernardo, C. E. Swenson, L. E. Bolsack, G. Horwith, S. DeWitt, E. Kelly, J. Klasterksy, J. P. Sculier, D. DeValeriola, E. Anaissie, G. Lopez-Berestein, A. Llanos-Cuentas, A. Boyle, and R. A. Branch. 1997. Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrob. Agents Chemother. 41:2201-2208.
2. Akaike, H. 1974. A new look at the statistical model identification. IEEE Trans. Automated Control 19:716-723.
3. Anaissie, E. J., R. O. Darouiche, D. Abi-Said, O. Uzun, J. Mera, L. O. Gentry, T. Williams, D. P. Kontoyiannis, C. L. Karl, and G. P. Bodey. 1996. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin. Infect. Dis. 23:964-972.
4. Banerjee, P., Q.-F. Liu, A. Louie, M. Shayegani, H. Taber, G. Drusano, and M. Miller. 1997. Comparison of checkerboard isobolograms and computer generated 3D-plots for evaluation of the in-vitro interactions between antifungal drugs, abstr. C-252a, p. 164. In Abstracts of the 97th General Meeting of the American Society for Microbiology. American Society for Microbiology, Washington, D.C.
5. Bannatyne, R. M., and R. Cheung. 1977. Discrepant results of amphotericin B assays on fresh versus frozen serum samples. Antimicrob. Agents Chemother. 12:550.
6. Beck-Sague, C. M., W. R. Jarvis, and the National Nosocomial Infections Surveillance System. 1993. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J. Infect. Dis. 167:1247-1251.
7. Brajtburg, J., W. G. Powderly, G. S. Kobayshi, and G. Medoff. 1990. Amphotericin B: current understanding of mechanism of action. Antimicrob. Agents Chemother. 34:183-188.
8. Como, J. A., and W. E. Dismukes. 1994. Oral azole drugs as systemic antifungal therapy. N. Engl. J. Med. 330:263-272.
9. Granich, G. G., G. S. Kobayashi, and D. J. Krogstad. 1986. Sensitive high-pressure liquid chromatographic assay for amphotericin B which incorporates an internal standard. Antimicrob. Agents Chemother. 29:584-588.
10. Grant, S. M., and S. P. Clissold. 1990. Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 39:877-916.
11. Jorgensen, J. H., G. A. Alexander, J. R. Graybill, and D. J. Drutz. 1981. Sensitive bioassay for ketoconazole in serum and cerebrospinal fluid. Antimicrob. Agents Chemother. 20:59-62.
12. Louie, A., G. L. Drusano, P. Banerjee, Q.-F. Liu, W. Liu, P. Kaw, M. Shayegani, H. Taber, and M. H. Miller. 1998. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob. Agents Chemother. 42:1105-1109.
13. Louie, A., Q.-F. Liu, G. L. Drusano, W. Liu, M. Mayers, E. Anaissie, and M. H. Miller. 1998. Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans. Antimicrob. Agents Chemother. 42:1512-1514.
14. Louie, A., W. Liu, D. A. Miller, A. C. Sucke, Q.-F. Liu, G. L. Drusano, M. Mayers, and M. H. Miller. 1999. Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans. Animicrob. Agents Chemother. 43:2831-2840.
15. Madu, A., C. Cioffe, U. Mian, M. Burroughs, E. Toumanen, M. Mayers, E. Schwartz, and M. Miller. 1994. Pharmacokinetics of fluconazole in cerebrospinal fluid and serum of rabbits: validation of an animal model used to measure drug concentration in cerebrospinal fluid. Antimicrob. Agents Chemother. 38:2111-2115.
16. Martin, E., F. Maier, and S. Bhakdi. 1994. Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum. Antimicrob. Agents Chemother. 38:1331-1338.
17. National Committee for Clinical Laboratory Standards. 1995. Reference method for broth dilution antifungal susceptibility testing for yeast. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Villanova, Pa.
18. Petrou, M. A., and T. R. Rogers. 1991. Interactions in vitro between polyenes and imidazoles against yeast. J. Antimicrob. Chemother. 27:491-506.
19. Redding, S., J. Smith, G. Farinacci, M. Rinaldi, A. Fothergill, J. Rhine-Chalber, and M. Pfaller. 1994. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation of in vitro susceptibility testing and DNA subtype analysis. Clin. Infect. Dis. 18:240-242.
20. Rex, J. H., J. E. Bennett, A. M. Sugar, P. G. Pappas, C. M. Van der Horst, J. E. Edwards, R. G. Washburn, W. M. Scheld, A. W. Karchmer, A. P. Dine, M. J. Levenstein, C. D. Webb, the Candidemia Study Group, and the NIAID Mycoses Study Group. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N. Engl. J. Med. 331:1325-1330.
21. Ruhnke, M., A. Eigler, E. Engelmann, B. Geiseler, and M. Trautmann. 1994. Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatment with fluconazole. Infection 22:132-136.
22. Sanati, H., C. F. Ramos, A. S. Bayer, and M. A. Ghannoum. 1997. Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models. Antimicrob. Agents Chemother. 41:1345-1348.
23. Sugar, A. M., C. A. Hitchcock, P. F. Troke, and M. Picard. 1995. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob. Agents Chemother. 39:598-601.
24. Wey, S. B., M. Mori, M. A. Pfaller, R. F. Woolson, and R. P. Wenzel. 1988. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch. Intern. Med. 148:2642-2645.